Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
UK Startups and Innovation
13APR

Tropic Biosciences raises $105m from Norwich

2 min read
17:59UTC

A gene-editing tropical crops company closed an oversubscribed Series C outside the London-Oxford-Cambridge corridor. Temasek and Corteva Catalyst are on the cap table.

← Back to State capital floods in, seed money drainsJump to analysis ↓
TechnologyDeveloping
Key takeaway

A Norwich gene-editing company raised $105m, proving deep-tech capital can reach beyond the Golden Triangle.

Tropic Biosciences, a Norwich-based gene-editing company focused on tropical crops, closed an oversubscribed $105m Series C co-led by Forbion and Corteva Catalyst⁠1. Temasek, Just Climate, and IQ Capital also participated. The round is one of the few large UK deep-tech raises located outside the London, Oxford, and Cambridge corridor.

Tropic works on gene-editing staple crops (bananas, coffee, rice) for disease resistance and yield improvement. The investor mix reflects the company's position at the intersection of food security and biotechnology: Corteva is a global agricultural sciences company, Temasek is Singapore's sovereign wealth fund with a strong food security mandate, and Just Climate focuses on climate-positive investment.

Norwich's presence in the round is notable. The city hosts the John Innes Centre and the Earlham Institute, two of the UK's strongest plant and genomic science institutions, but the region has not historically attracted venture capital at this scale. Tropic's success suggests that deep-tech companies rooted in genuine research clusters can raise internationally even without a London address, provided the science is strong and the commercial application (food supply resilience) has a clear global buyer.

Deep Analysis

In plain English

Tropic Biosciences is a company based in Norwich that uses gene-editing (not genetic modification in the traditional sense) to develop crop varieties that are more disease-resistant, drought-tolerant, or longer-lasting. It works primarily on tropical crops like bananas and coffee. It raised $105m, meaning investors gave it that money in exchange for a share of the company. Unusually for UK deep tech investment, which clusters heavily around London, Cambridge, and Oxford, this company is in Norwich. Its success demonstrates that significant investment can reach UK tech companies outside the traditional funding hubs.

What could happen next?
  • Opportunity

    Tropic's raise demonstrates that deep-tech companies outside the London-Oxford-Cambridge corridor can attract major international institutional investors, potentially encouraging more regional deep-tech investment.

Sources:The Next Web
Mentions:Tropic Biosciences →Forbion →Corteva Catalyst →Temasek →Spark Capital →Cambridge →Just Climate →John Innes Centre →Wyss Institute →IQ Capital →
First Reported In

Update #1 · State capital floods in, seed money drains

The Next Web· 13 Apr 2026
Read original →
Different Perspectives
Nscale and Open Cosmos
Nscale and Open Cosmos
Nscale chose the New York Stock Exchange for its listing on 18 September, putting Britain's largest AI infrastructure bet to American public investors rather than British ones. Open Cosmos took the opposite route four days earlier, raising nine figures from an all-domestic syndicate on five years of profit, evidence that staying is possible when the balance sheet allows it.
Dame Chi Onwurah and the Science, Innovation and Technology Committee
Dame Chi Onwurah and the Science, Innovation and Technology Committee
Committee chair Dame Chi Onwurah wrote to government on 7 September asking how Matt Clifford's conflict at ARIA arose and what safeguards protect its governance, and expects a detailed response. Her question has not yet been put to the Sovereign AI Unit, whose own chair sits at a venture capital firm while overseeing state AI equity.
The Entrepreneurs Network
The Entrepreneurs Network
The Entrepreneurs Network's founder survey found 65% say Britain is easy to start a business in but only 14% say it is easy to scale one, with 82% negative on tax and 74% finding investment hard to access. On this reading the constraint is regulation and tax, not the capital-vehicle design the state keeps adjusting.
New Economics Foundation
New Economics Foundation
The New Economics Foundation argues fiscal accounting rules, not political will, cap what Britain's state capital vehicles can do. Matching the KfW and Bpifrance benchmark of 1% of GDP would need the National Wealth Fund to deploy roughly GBP21bn a year by 2028-29, about four times its current capacity.
Competition and Markets Authority
Competition and Markets Authority
The CMA's 8 September report on public procurement asked whether Britain's roughly GBP400bn state-spending system is built to grow high-potential firms rather than simply widen SME participation. Its Recommendation 5 calls for a dedicated frontier-technology procurement framework, an official acknowledgement that today's design may serve the wrong target.
Highland Europe
Highland Europe
Highland Europe, the growth-equity firm behind a €1bn-plus fund, took €65m from the British Business Bank into its Technology Growth Fund VI on 30 July via British Patient Capital. For a Geneva-based growth investor, the Bank's cheque is routine cornerstone capital, unrelated to which Whitehall department currently claims to sponsor UKRI.